The Maharashtra Food and Drug Administration has directed hospitals to stop forcing patients to buy medicines from in-house pharmacies. Hospitals must now provide patients with physical prescriptions and allow them to choose any licensed pharmacy for their medicine needs. This policy aims to increase patient choice and improve transparency in healthcare billing across the state.
The Maharashtra Food and Drug Administration (FDA) has issued a mandatory directive to all healthcare institutions across the state, prohibiting the practice of forcing patients to purchase medicines exclusively from hospital-affiliated pharmacies. This regulatory step is designed to break what the authorities describe as a captive market, where patients receiving treatment are often compelled to buy drugs at counters within the premises, regardless of price or convenience.
New Requirements for Healthcare Facilities
Under the new order, all hospitals must ensure that patients are provided with a clear prescription for their medication. Furthermore, these institutions are required to display notices in both Marathi and English. These signs must explicitly inform patients that they have the legal right to purchase prescribed medicines from any pharmacy of their choice, whether inside or outside the hospital campus. The regulator aims to ensure that patient autonomy is protected during the treatment process.
Business Model and Financial Context
While many hospitals operate in-house pharmacies to ensure medication availability, especially for urgent or complex treatments, the FDA's intervention highlights concerns that these facilities are sometimes used as a primary revenue stream. By mandating transparency, the state government is attempting to reduce the financial burden on patients. However, experts note that simply increasing choice may not immediately lower the cost of medicines. A significant component of the final price paid by consumers includes trade margins—the profit margins built into the price at each stage of the supply chain, from the manufacturer to the stockist and the final retailer.
Addressing Medicine Costs
Historical efforts to manage drug costs have focused on capping these trade margins. For instance, interventions by the National Pharmaceutical Pricing Authority (NPPA) in 2019 demonstrated that price caps on specific life-saving drugs, such as those used for cancer treatment, could lead to substantial cost reductions for patients. The Maharashtra FDA directive is seen as a move toward greater transparency, but industry analysts suggest that deeper reforms, such as mandatory itemized billing and broader trade margin controls, would be necessary to achieve a significant reduction in overall healthcare expenses. The focus for investors in the pharmacy and hospital sector will be how these regulations influence future revenue models, particularly for chains that rely heavily on in-house retail margins to support their hospital operations. The next phase for observers will be monitoring compliance levels across private healthcare networks and any follow-up enforcement actions by the state regulator to ensure these new rules are effectively implemented.